Bacteriophages, yeast, mRNA display: Who is the champion of the display technology?-Yeast Display Technology Special Topic-Tekbiotech-Yeast and Phage Display CRO, Expert in Nano-body and Antibody Drug Development

Bacteriophages, yeast, mRNA display: Who is the champion of the display technology?

Previously, we published the “Introduction to Phage Display,” “Technical Aspects,” and “Applications” series. We believe these articles provide an in-depth understanding of phage display technology. However, no scientific method is perfect, and phage display is no exception. As a result, scientific and technological advancements continue to evolve, and yeast display and mRNA display technologies have also emerged onto the scene. Are you wondering which method to choose? To evaluate their relative merits, you first need to understand how they work.

1. Technical Principles:

①　Phyde Display

The core principle of phage display involves fusing the gene for a foreign peptide or protein with the gene for a specific capsid protein. As the phage assembles, the exogenous molecule is displayed on the phage surface, while the corresponding gene remains inside the phage. This precisely links the phenotype to the genotype, laying the foundation for downstream modifications.

② Yeast Display

Baker’s yeast is a commonly used and ideal host for this technology. Among the various systems available, the baker’s yeast α-aggrecin system is the most popular. The yeast cell wall has a “sandwich” structure: mannan (outer layer) – protein (middle layer) – glucan (inner layer). This structure provides the foundation for the display of exogenous proteins. Display mechanism: Exogenous proteins bind to the host’s anchor proteins (composed of Aga2p and Aga1p) and are displayed on the cell surface.

Eukaryotic systems ensure proper protein folding and modification, allowing for direct quantitative, high-throughput screening and sorting via flow cytometry.

③　mRNA Display

Essentially, mRNA display is a “directed evolution” platform implemented in vitro, completely free from the limitations of cellular transformation efficiency. It links protein function (phenotype) to its encoding gene (genotype) through a puromycin-mediated covalent bond, thereby enabling the efficient selection of protein molecules with desired functions from a vast pool of random sequences through multiple rounds of “screening-amplification” cycles.

Its unique advantages over cell-based display include a cell-free format and massive library capacity.

核糖体上mRNA-蛋白融合的形成-1.png

Figure 1: Formation of mRNA-protein fusions on ribosomes

mRNA展示技术完整流程-2.png

Figure 2: Complete workflow of mRNA display technology

2. Comprehensive Performance Comparison: A Single Chart to Understand the “Ranking of Champions”

Dimension	Phage Display	Yeast Display	mRNA Display
Library Capacity	High (10? - 1011)	Medium (10? - 10?)	Ultra-high (1013 - 101?)
Screening Throughput	High	Ultra-high (Flow Cytometry)	High
Expression System	Prokaryotic (E. coli)	Eukaryotic (Yeast)	Cell-free System
Protein Folding Quality	Average, no glycosylation	Excellent, supports glycosylation and other modifications	Simple, no complex modifications
Affinity Maturation Efficiency	Dependent on library construction and panning strategies	Extremely high; quantitative optimization via flow sorting	Extremely high; massive library capacity serves as evolutionary engine
Screening Cycle	Long (requires infection and amplification)	Medium	Ultra-short (cell-free workflow)
Technical Barrier & Cost	Relatively low, well-established classic technology	Medium	High (complicated workflow, expensive reagents)

3. Application Scenarios:

①　Choosing Phage Display:

? When you want to rapidly and cost-effectively screen antibody fragments (e.g., ScFv, Fab) or peptides;

? For epitope mapping or protein interaction studies;

? When the project is in the early discovery and preliminary screening stages.

②　Choosing Yeast Display:

? For affinity maturation of full-length antibodies or complex proteins;

? When screening for highly stable, highly expressed antibody molecules;

? When a project is in the critical stage of antibody engineering and optimization.

③ When to Choose mRNA Display:

? To explore novel, non-antibody binding scaffolds (e.g., DARPin, Affibody);

? Constructing and screening peptide libraries containing non-natural amino acids;

? The core requirement of the research is to maximize library capacity and sequence diversity.

In fact, there is no single “best” technology; rather, the appropriate technology must be selected based on the specific context. These three methods are not inherently superior or inferior to one another. Now that you have carefully reviewed the differences between them, do you know which method to choose for your next experiment?

Based on phage display and yeast display technologies, Tek BioTech (Tianjin) Co., Ltd. has established a comprehensive platform for targeted antibody drug discovery, capable of providing scientists worldwide with high-quality development services for various types of monoclonal antibodies, including scFv, VHH, and Fab, and is capable of developing various functional and structurally distinct antibodies (including, but not limited to, neutralizing antibodies, conformation-specific antibodies, and cross-reactive antibodies). Additionally, TekBio offers complementary downstream services such as antibody expression validation, antibody humanization design and validation, antibody affinity maturation, and CAR-T candidate sequence design to meet the diverse needs of clients in antibody drug development.

References:

[1] Liu R,Barrick JE,Szostak JW, et al. Optimized synthesis of RNA-protein fusions for in vitro protein selection. Methods Enzymol. 2000;318:268-93.

[2] Hammond PW,Alpin J,Rise CE, et al. In vitro selection and characterization of Bcl-X(L)-binding proteins from a mix of tissue-specific mRNA display libraries. J Biol Chem. 2001;276 (24):20898-906.

Previous:Breakthrough: Ultra-High Sensitivity Detection of Legionella Using an Aptamer-Based Electrochemical Sensor Next:None!